Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. That said, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.
VF Corp (VFC)
Consensus Price Target: $18.77 (41.8% implied return)
Owner of The North Face, Vans, and Supreme, VF Corp (NYSE: VFC) is a clothing conglomerate specializing in branded lifestyle apparel, footwear, and accessories.
Why Do We Pass on VFC?
- Products and services have few die-hard fans as sales have declined by 2.1% annually over the last five years
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
VF Corp is trading at $13.24 per share, or 11.7x forward P/E. Check out our free in-depth research report to learn more about why VFC doesn’t pass our bar.
Trinity (TRN)
Consensus Price Target: $34 (20.3% implied return)
Operating under the trade name TrinityRail, Trinity (NYSE: TRN) is a provider of railcar products and services in North America.
Why Do We Think Twice About TRN?
- Backlog has dropped by 24.9% on average over the past two years, suggesting it’s losing orders as competition picks up
- Estimated sales for the next 12 months are flat and imply a softer demand environment
- Cash burn makes us question whether it can achieve sustainable long-term growth
At $28.26 per share, Trinity trades at 16.1x forward P/E. To fully understand why you should be careful with TRN, check out our full research report (it’s free).
Novavax (NVAX)
Consensus Price Target: $14.00 (37.5% implied return)
Pioneering a nanoparticle technology that mimics the molecular structure of disease pathogens, Novavax (NASDAQ: NVAX) develops and commercializes protein-based vaccines for infectious diseases, with a primary focus on its COVID-19 vaccine and combination respiratory vaccine candidates.
Why Are We Bearish on NVAX?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 18.9% annually over the last five years
- Adjusted operating profits fell over the last two years as its sales dropped and it struggled to adjust its fixed costs
- Negative free cash flow raises questions about the return timeline for its investments
Novavax’s stock price of $10.18 implies a valuation ratio of 7x forward price-to-sales. If you’re considering NVAX for your portfolio, see our FREE research report to learn more.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
